Select Language
EGF R
EGF R Overview
| English Name | Epidermal growth factor receptor erbB1 | Approved Drugs | 39 |
| Drugs in Clinical Trials | 203 | Target Synonym | Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1 |
| Highest Development Stage | Approved | ||
| English Name | Epidermal growth factor receptor erbB1 |
| Target Synonym | Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1 |
| Approved Drugs | 39 |
| Drugs in Clinical Trials | 203 |
| Highest Development Stage | Approved |
EGF R Product List
- Product Category
Protein (19)Beads (1)Antibody (1)Cell (1)
- Product Status
Launched (22)
- Species
Human (14)Mouse (4)Rhesus macaque (2)Rabbit (2)
- Tag
His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (3)Llama IgG Fc Tag (1)Fc Tag & Avi Tag (2)Tag Free (1)
- Conjugate
Unconjugated (11)Biotin-labeled (4)FITC Labeled (2)- (2)PE Labeled (2)APC Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT EGR-H5222 |  Human | HEK293 | Human EGF R Protein, His Tag (MALS verified) |  |  |  |
HOT EGR-H5252 | Human | HEK293 | Human EGF R Protein, Fc Tag (MALS verified) |  | | |
HOT EGR-H82E3 | Human | HEK293 | Biotinylated Human EGF R Protein, His,Avitag™ (MALS verified) |  | | |
HOT EGR-H82F8 | Human | HEK293 | Biotinylated Human EGF R Protein, Fc,Avitag™ (MALS verified) |  | | |
HOT EGR-HA2H8 | Human | HEK293 | APC-Labeled Human EGF R Protein, His TagStar Staining | |||
CHEK-ATP148 | Human | HEK293 | HEK293/Human EGF R Stable Cell Line |  | ||
EGR-H5213 | Human | HEK293 | Human EGF R Protein, Tag Free (MALS verified) |  | | |
EGR-H522a | Human | HEK293 | Human EGF R Protein, His Tag, low endotoxin (MALS verified) |  | | |
EGR-H5259 | Human | HEK293 | Human EGF R Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified) |  | | |
EGR-HF256 | Human | HEK293 | FITC-Labeled Human EGF R Protein, Fc Tag |  | | |
Total: 22
- 1
- 2
- 3
EGF R Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
EGF R Synonyms
EGFR,ERBB,ERBB1,HER1,PIG61,mENA
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| YK-029A | YK-029A; YK-209A; YK-209-A; YK-029-A | Phase 3 Clinical | Hainan Yuekang Biomedicine Co Ltd | Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions | Details |
| Sutetinib Maleate | Phase 3 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details | |
| Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Lung Neoplasms | Details |
| Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Anus Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms | Details |
| Sacibertinib | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
| HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Medullary thyroid cancer (MTC); Neoplasms; Solid tumours | Details |
| Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm Jsc | Head and Neck Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| BEBT-109 | BEBT-109 | Phase 3 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
| Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Cardiomyopathies; Endomyocardial Fibrosis | Details | |
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Ruserontinib | SKLB-1028 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd, Sichuan University | Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Solid tumours | Details |
| Pimurutamab | HLX-07 | Phase 3 Clinical | Carcinoma, Adenosquamous; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Nasopharyngeal Carcinoma; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details | |
| Becotatug | JMT-101 | Phase 3 Clinical | Shanghai Jmt-Bio Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuxima-β | Phase 3 Clinical | Sun Yat-Sen University | Colorectal Neoplasms | Details | |
| HS-20117 | HS-20117; PM1080; PM-1080 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| SYS-6010 | SYS-6010; CPO-301; CPO301; SYS6010 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| IAE-0972 | IAE-0972 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
| Depatuxizumab mafodotin | ABT-414; ABT-414/806 | Phase 3 Clinical | Abbvie Inc | Carcinoma, Squamous Cell; Glioblastoma; Glioma; Gliosarcoma | Details |
| EG-007 | EG-007 | Phase 3 Clinical | Evergreen Therapeutics Inc | Endometrial Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours | Details |
| Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 2 Clinical | Dingfu Biotarget Co Ltd | Ascites; Pleural Effusion, Malignant; Solid tumours | Details |
| Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | GC Biopharma Corp | Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Macular Degeneration; Neoplasms; Solid tumours | Details |
| HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
| WSD-0922 | WSD0922; WSD-0922 | Phase 2 Clinical | Wayshine Biopharm International Ltd | Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma | Details |
| C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
| Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Triple Negative Breast Neoplasms | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive | Details |
| BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 2 Clinical | Blue Blood Biotech Corp, National Cheng Kung University | Diabetic Foot | Details |
| Gozanertinib | ABT-101; DBPR-112 | Phase 2 Clinical | National Health Research Institutes | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours | Details |
| Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Brain Neoplasms; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Biliary Tract Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 2 Clinical | Array Biopharma | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 2 Clinical | Umcg The University Medical Center Groningen | Lung Neoplasms; Penile Neoplasms; Rectal Neoplasms | Details | |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| VBC-101-F11 | VBC-101; VBC101F11; VBC101 | Phase 2 Clinical | Shanghai Orange Sail Pharmaceutical Co Ltd | Solid tumours | Details |
| EHT-102 | EHT-102; EHT-0102 | Phase 2 Clinical | Diaxonhit | Autosomal recessive deafness-9; Breast Neoplasms; Colonic Neoplasms; Hearing Loss; Ovarian Neoplasms | Details |
| NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms | Details |
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
| JY-016 | JY-016 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Colorectal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| ABL-104 | ABL-104; YH-32364 | Phase 2 Clinical | Abl Bio Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Enozertinib | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Silevertinib | BDTX-1535 | Phase 2 Clinical | Black Diamond Therapeutics Inc | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Glioblastoma; Glioma | Details |
| Anti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy | Phase 2 Clinical | University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| 89Zr-DFO-Nimotuzumab | Phase 2 Clinical | University Of Saskatchewan | Colorectal Neoplasms; Lung Neoplasms | Details | |
| Kenitinib | Phase 2 Clinical | Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung; Lymphoma, B-Cell | Details | |
| TQB-6411 | TQB-6411; TQB6411 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Esophageal Neoplasms; Lung Neoplasms; Neoplasms | Details |
| JS-212 | JS212; JS-212 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Solid tumours | Details |
| BH-30643 | BH-30643 | Phase 2 Clinical | BlossomHill Therapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| FH-006 | FH-006; FH006 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Fuhong Biomedical Co Ltd | Lung Neoplasms; Solid tumours | Details |
| SKB-571 | SKB-571; MK-2750; SKB571 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| DB-1418 | AVZO-1418; DB-1418 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Lung Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| WSD-0922-FU | WSD0922-FU; WSD-0922-FU | Phase 2 Clinical | Wayshine Biopharm International Ltd | Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours | Details |
| KY-0301 | RB-601; KY-0301 | Phase 2 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours | Details |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours; Uterine Neoplasms | Details |
| PRO-1286 | PRO-1286; GEN1286; GEN-1286 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Neoplasms; Solid tumours | Details |
| TQB-2922 | TQB2922; TQB-2922 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Colorectal Neoplasms; Neoplasms | Details |
| TRX-221 | TRX-221 | Phase 2 Clinical | Therapex Corp | Carcinoma, Non-Small-Cell Lung | Details |
| E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms | Details |
| IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Solid tumours | Details | |
| SHR-9839 | SHR-9839; SHR9839 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| DF9001 | DF-9001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
| BBT-207 | BBT-207 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| DAJH-1050766 | DAJH1050766; DA-0157; DAJH-1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Shenzhen Pregene Biopharma Co Ltd | Colorectal Neoplasms | Details | |
| HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| AP-L1898 | AP-L1898; JS111; WJ-002 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| CKD-702 | CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms | Details |
| Marlotamig | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
| Epertinib | S-222611; RT1978; RT-1978 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Ankang Biotechnology Co Ltd | Colorectal Neoplasms | Details | |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Pancreatic Neoplasms | Details | |
| Ascorbic Acid/Menadione | Phase 2 Clinical | Ic-Medtech Co, Summa Health System | Joint Diseases; Prostatic Neoplasms | Details | |
| Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| TQB3804 | TQB-3804 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| D2C7-IT | D2C7-(scdsFv)-PE38 KDEL; scds-D2C7 -PE38KDEL; D2C7-Immunotoxin; D2C7-IT | Phase 1 Clinical | Duke University, Istari Oncology Inc | Glioblastoma; Glioma | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | Details | |
| BPI-15086 | BPI-15086; BPI-15000 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Carcinoma; Colorectal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours | Details |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Advenchen Laboratories Llc, Jiangsu Simcere Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Melanoma; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| TQ-B3395 | TQ-B-3395; TQ-B3395; CT-1495 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| Antibody-drug nanocell conjugates (EnGeneIC) | EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox | Phase 1 Clinical | Engeneic Ltd | Glioblastoma | Details |
| Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Colorectal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms | Details | |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| [89Zr]Panitumumab | Phase 1 Clinical | Stanford University, University Of Alabama At Birmingham, Vanderbilt-Ingram Cancer Center | Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 1 Clinical | Symphogen A/S | Carcinoma; Colorectal Neoplasms; Glioma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Hemay-020 | Hemay-020 | Phase 1 Clinical | Hainan General Sanyang Pharmaceutical Co Ltd, Tianjin Hemay Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Erlotinib gel (Sol-Gel Technologies) | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
| ZN-e4 | ZN-e4; KP-673 | Phase 1 Clinical | Zeno Pharma, Zentalis Pharmaceuticals LLC | Carcinoma, Non-Small-Cell Lung | Details |
| LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Neoplasms | Details | |
| Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
| E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine) | Phase 1 Clinical | University Of California San Francisco | Glioblastoma | Details | |
| 64Cu-NCAB-001 | Phase 1 Clinical | Japan Agency For Medical Research And Development | Pancreatic Neoplasms | Details | |
| anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) | EGFR-806 | Phase 1 Clinical | Seattle Children'S Hospital | Central Nervous System Neoplasms; Solid tumours | Details |
| recombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology) | Phase 1 Clinical | Shanghai Humantech Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details | |
| anti-EGFRvIII CAR T-cell therapy (Beijing Marino) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma | Details | |
| naputinib tosilate (Shenzhen Neptunus Bioengineering) | NEP-015 | Phase 1 Clinical | Shenzhen Neptunus Bioengineering Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| VRN-11 | VRN11; VRN-110755 | Phase 1 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Solid tumours | Details |
| HLX-42 | HLX-42; HLX42 | Phase 1 Clinical | Hanlin Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| PF-08046052 | LAVA-1223; SGN-EGFRd2 | Phase 1 Clinical | Lava Therapeutics NV, Seagen Inc, Vu University Medical Center | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
| BLU-701 | BLU-701; BLU 701 | Phase 1 Clinical | Blueprint Medicines Corp | Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Lung Neoplasms; Neoplasms; Neoplasms, Nerve Tissue; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms | Details |
| NEOK-002 | ABL209; ABL-209; NEOK002; NEOK-002 | Phase 1 Clinical | Abl Bio Inc, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Neoplasms; Solid tumours | Details |
| QLS-5316 | QLS5316; QLS-5316 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| HDM-2024 | HDM2024; HDM-2024 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Solid tumours | Details |
| 188Re-nimotuzumab | Phase 1 Clinical | Cuban Center For Molecular Immunology | Glioma | Details | |
| SIM-0610 | SIM-0610; SIM0610 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HJ-004-02 | HJ-004-02; HJ00402 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| TJ-101 (Phrontline Biopharma) | TJ-101 | Phase 1 Clinical | Phrontline Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| HLX-48 | HLX-48 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| EPI-326 | EPI-326 | Phase 1 Clinical | EpiBiologics | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Humanwell Healthcare (Group) Co Ltd | Colorectal Neoplasms | Details | |
| HS-20122 | HS-20122; HS20122 | Phase 1 Clinical | Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| ALK-202 | ALK-202; ALK202 | Phase 1 Clinical | Shanghai Allink Biotherapeutics Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Solid tumours | Details |
| GenSci-139 | GenSci-139; GenSci139 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Panitumumab biosimilar(Generium) | GNR-107 | Phase 1 Clinical | Generium Pharmaceuticals | Colorectal Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | Details |
| BG-60366 | BG-60366 | Phase 1 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| TQB-3002 | TQB3002; TQB-3002 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| PM1300 | PM-1300; PM1300 | Phase 1 Clinical | Neoplasms | Details | |
| SAR-446368 | SAR446368; SAR-446368; VIR-5525; AMX-525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| DWP709 | DWP709; DWP-818-1 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Epidermolysis Bullosa | Details |
| CMDE-005 | CMDE005; CMDE-005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| BG-T187 | BG-T187; BGT187 | Phase 1 Clinical | BeOne Medicines Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Solid tumours | Details | |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HJ-002-03 | HJ-002-03; HJ00203 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YL-221 | YL221; YL-221 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| HS-10504 | HS10504; HS-10504 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| BPI-520105 | BPI-520105; BPI520105 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | Details |
| FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| FPI-2053 | FPI-2053 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| DM-005 | DM005; YH013; DM-005 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| FPI-2068 | FPI-2068; [225Ac]-FPI-2068; AZD-2068 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| HSK-40118 | HSK40118; HSK-40118 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Tilatamig samrotecan | AZD9592; AZD-9592 | Phase 1 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Neoplasms; Solid tumours | Details |
| NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
| BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details | |
| QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Losatuxizumab vedotin | ABBV-221; ABBV221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Lung Neoplasms; Triple Negative Breast Neoplasms | Details |
| DXC004A | DXC-004-A; DXC004A | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Head and Neck Neoplasms; Lung Neoplasms; Solid tumours | Details |
| BB-1705 | BB-1705 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
| EGFR IL12 CART | Phase 1 Clinical | Shenzhen Pregene Biopharma Co Ltd | Colorectal Neoplasms | Details | |
| ERAS-801 | ERAS-801; JGK-068S | Phase 1 Clinical | Regents Of The University Of California | Astrocytoma; Glioblastoma | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| [111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| BGC-0902 | BGC-0902; BG-C0902; BGC0902 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd | Neoplasms; Solid tumours | Details |
| ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Solid tumours | Details |
| HLX-35 | HLX-35; BNA035 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details | |
| WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| FCN-411 | FCN-411 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details | |
| ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
| ABY-029 | ABY-029 | Phase 1 Clinical | Affibody Ab, Dartmouth College, Li-Cor Bioscience | Brain Neoplasms; Glioma; Head and Neck Neoplasms; Sarcoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Lifirafenib | BeiGene-283; BGB-283 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
| 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 | Clinical | Harbin Medical University | Lung Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Menadione | Approved | Eli Lilly And Company | Kyrbax | United States | null | Exanthema; Hypoprothrombinemias; Vitamin K Deficiency Bleeding | Details | |||
| PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
| Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) | STI-001; CMAB-009 | Approved | Shanghai Zhangjiang Biotechnology Co Ltd | Enlituo, 恩立妥 | Mainland China | Colorectal Neoplasms | Taizhou Mabtech Pharmaceutical Co Ltd | 2024-06-18 | Colorectal Neoplasms; Neoplasms | Details |
| Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Rakuten Medical Inc | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Colorectal Neoplasms | Imclone Gmbh | 2004-02-12 | Adenocarcinoma, Mucinous; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Chordoma; Colonic Neoplasms; Colorectal Neoplasms; Complex Regional Pain Syndromes; Endometrial Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Granuloma, Lethal Midline; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neoplastic Cells, Circulating; Neuralgia; Nose Neoplasms; Oropharyngeal Neoplasms; Oropharyngeal Squamous Cell Carcinoma (OPSCC); Ovarian Neoplasms; Pancreatic Neoplasms; Papilloma, Inverted; Paranasal Sinus Neoplasms; Peritoneal Neoplasms; Precancerous Conditions; | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Diseases; Lung Neoplasms; Lymphoma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neuroectodermal Tumors; Penile Squamous Cell Carcinoma; Prostatic Neoplasms; Renal Insufficiency; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Neoplasms | Details |
| Mifanertinib Maleate | MET-306 | Approved | Suzhou Maitai Bio-Technology Co Ltd | 迈瑞东 | Mainland China | Carcinoma, Non-Small-Cell Lung | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | 2025-10-21 | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
| Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Burns; Skin Ulcer | Details | |
| Becotatug vedotin | MRG-003; MRG003 | Approved | Shanghai Miracogen Inc | 美佑恒 | Mainland China | Nasopharyngeal Carcinoma | Lepu Biopharma Co Ltd | 2025-10-28 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms | Details |
| Nimotuzumab | TheraCIMh-R3; YMB-1000; OSAG-10; KI-0502; KI-0501; DE-766; h-R3; OSAG-101; OSAG101 | Approved | Center Of Molecular Immunology, Cimym Biosciences | BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher, Theraloc, Taixinsheng | India | Head and Neck Neoplasms; Nasopharyngeal Neoplasms | null | 2006-07-21 | Anus Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Diseases; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Glioma; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Center For Genetic Engineering And Biotechnology, Praxis Pharmaceuticals | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
| Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | EU | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Cheplapharm Registration GmbH | 2004-11-18 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adenomatous Polyposis Coli; Adenomatous Polyps; Anus Neoplasms; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Brenner Tumor; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Cholangitis, Sclerosing; CNS Embryonal Tumor; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Ependymoma; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioblastoma; Glioma; Glioma, Subependymal; Gliosa | Details |
| Gefitinib | ZD-1839 | Approved | Astrazeneca Plc | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Abdominal Neoplasms; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Follicular; Adrenocortical Carcinoma; Astrocytoma; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Granuloma, Lethal Midline; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Insulinoma; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leukemia, Myeloid, Acute; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Medullary thyroid cancer (MTC); Mesotheliom | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Brain metastases; Carcinoma; Carcinoma, Non-Small-Cell Lung; Ependymoma; Granuloma, Plasma Cell; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Meningioma; Myofibroma; Neoplasms; Neurilemmoma; Neurofibromatosis 2; Neuroma, Acoustic; Sarcoma, Kaposi; Solid tumours | Details |
| Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
| Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Alopecia; Diabetic Foot; Dry Eye Syndromes | Details |
| Panitumumab N01 | QL-1203; QL1203 | Approved | Qilu Pharmaceutical Co Ltd | 安可泽 | Mainland China | Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2025-12-03 | Colorectal Neoplasms; Solid tumours | Details |
| Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neurofibromatosis 2; Neuroma, Acoustic; Psoriasis; Solid tumours; Stomach Neoplasms | Details |
| Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
| Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Burns; Diabetic Foot | Details | |
| Lazertinib Mesylate | YH-25448; JNJ-73841937; JNJ-1937; GNS-1480 | Approved | Janssen Biotech Inc, Oscotec Inc, Yuhan Corp | Leclaza, 利珂, Lazcluze | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency | Details |
| Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Burns; Diabetic Foot | Details | |
| Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
| Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Eli Lilly And Co (Ireland) Ltd | 2015-11-24 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| Cetuximab N01 | KL-A140; KLA140; A-140; KL-140; KLA-140 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 达泰莱 | Mainland China | Colorectal Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-01-24 | Adenocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Neoplasms; Rectal Neoplasms | Details |
| Amivantamab/Hyaluronidase | Approved | Janssen Biotech Inc | Rybrevant Faspro, 锐珂捷 | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2025-12-17 | Carcinoma, Non-Small-Cell Lung | Details | |
| Panitumumab | ABX-0303; E7.6.3; ABX-10221; AMG-954; ABX-EGF | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Adenoma, Pleomorphic; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Exanthema; Gastrointestinal Neoplasms; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Malignant Carcinoid Syndrome; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Neratinib Maleate | HKI-272; PF-0528767; WAY-179272; CAN-030; PB-272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳, 赫赛佳, Hernera | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Abdominal Neoplasms; Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Nervous System Neoplasms; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Medulloblastoma; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Gonadal Tissue; Neurofibromatosis 2; Neuroma, Acoustic; Nose Neoplasms; Oligoden | Details |
| Sevabertinib | BAY-2927088 | Approved | Bayer AG, Broad Institute, Harvard University | Hyrnuo | United States | Carcinoma, Non-Small-Cell Lung | Bayer Healthcare Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Llc | 2025-11-19 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Liver Diseases; Neoplasm Metastasis; Solid tumours | Details |
| Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
| Amivantamab | JNJ-61186372; JNJ-372; JNJ-6372; CNTO4424; CNTO-4424 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Adenocarcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Lung Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Adenocarcinoma; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Glioblastoma; Head and Neck Neoplasms; Liver Diseases; Lung Neoplasms; Mouth Neoplasms; Neoplasm Metastasis; Neoplasms; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: